Mostra i principali dati dell'item
Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study
dc.creator | Tsimihodimos V., Bargiota A., Pagkalos E.M., Manes C., Papas A., Karamousouli E., Voss B., Elisaf M.S. | en |
dc.date.accessioned | 2023-01-31T10:14:29Z | |
dc.date.available | 2023-01-31T10:14:29Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.1055/a-0824-6607 | |
dc.identifier.issn | 09477349 | |
dc.identifier.uri | http://hdl.handle.net/11615/79975 | |
dc.description.abstract | Background Metformin, in the absence of contraindications or intolerance, is recommended as first-line treatment for patients with type 2 diabetes mellitus (T2DM). This observational, retrospective study assessed the real-world adequacy of glycaemic control in Greek patients with T2DM initiating metformin monotherapy at maximum tolerated dose. Methods Included patients received metformin monotherapy for ≥24 months; relevant patient data were collected immediately prior to metformin initiation (baseline) and at other prespecified time points. The primary objective was to report, after 9 months of metformin treatment, the percentage of patients with baseline glycated haemoglobin (HbA 1c) levels ≥6.5% (≥48 mmol/mol) achieving HbA 1c <6.5%. Secondary objectives included the assessment of time spent with poor glycaemic control and time to treatment intensification. A sensitivity analysis assessed the percentage of patients with baseline HbA 1c ≥7% (≥53 mmol/mol) achieving HbA 1c <7% (<53 mmol/mol). Results Of the enrolled patients (N=316), 247 had baseline HbA 1c ≥6.5%; following 9 months on metformin, 90 (36.4%) patients achieved HbA 1c <6.5% (mean HbA 1c change-1.3% [-14 mmol/mol]). Median time of exposure to HbA 1c ≥6.5% was 23.4 months and time to treatment intensification was 28.0 months. The sensitivity analysis revealed that the proportion of patients achieving HbA 1c <7.0% was 50% (mean HbA 1c py for up to 24 months. Addressing clinical inertia could improve disease outcomes and, possibly, economic burden. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York. | en |
dc.language.iso | en | en |
dc.source | Experimental and Clinical Endocrinology and Diabetes | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083022796&doi=10.1055%2fa-0824-6607&partnerID=40&md5=95cd2fd6c20eb96266526cc5bc742cd6 | |
dc.subject | dipeptidyl peptidase IV inhibitor | en |
dc.subject | glucagon like peptide 1 receptor agonist | en |
dc.subject | hemoglobin A1c | en |
dc.subject | insulin | en |
dc.subject | metformin | en |
dc.subject | sulfonylurea | en |
dc.subject | antidiabetic agent | en |
dc.subject | glycosylated hemoglobin | en |
dc.subject | hemoglobin A1c protein, human | en |
dc.subject | metformin | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | economic aspect | en |
dc.subject | female | en |
dc.subject | glycemic control | en |
dc.subject | Greek (people) | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | maximum tolerated dose | en |
dc.subject | metabolic regulation | en |
dc.subject | middle aged | en |
dc.subject | monotherapy | en |
dc.subject | non insulin dependent diabetes mellitus | en |
dc.subject | observational study | en |
dc.subject | priority journal | en |
dc.subject | retrospective study | en |
dc.subject | time to treatment | en |
dc.subject | treatment outcome | en |
dc.subject | blood | en |
dc.subject | drug effect | en |
dc.subject | Greece | en |
dc.subject | non insulin dependent diabetes mellitus | en |
dc.subject | Aged | en |
dc.subject | Diabetes Mellitus, Type 2 | en |
dc.subject | Female | en |
dc.subject | Glycated Hemoglobin A | en |
dc.subject | Greece | en |
dc.subject | Humans | en |
dc.subject | Hypoglycemic Agents | en |
dc.subject | Male | en |
dc.subject | Maximum Tolerated Dose | en |
dc.subject | Metformin | en |
dc.subject | Middle Aged | en |
dc.subject | Outcome Assessment, Health Care | en |
dc.subject | Retrospective Studies | en |
dc.subject | Georg Thieme Verlag | en |
dc.title | Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |